ChromaVision Medical Systems (San Juan Capistrano, California), a technology and services resource for pathologists, oncologists and the pharmaceutical industry, said that it is changing its name to Clarient "in order to better reflect a new strategy, direction and business plan that have been expanded to serve three distinct markets."

The company expects the name change to be in effect by March 15. It has reserved the ticker symbol CLRT with Nasdaq, and the company's shares are expected to begin trading under that new symbol in mid-March.

Under the Clarient name, the company will be organized into three business units: diagnostic services, which provides a full range of onsite and remote advanced cancer diagnostic testing; biopharmaceutical services, which provides technology to drug companies in pursuit of a new targeted cancer therapies; and the company's legacy imaging equipment product line.

No Comments